Copenhagen, Denmark - January 5, 2016: IO Biotech today announced the successful completion of a €11 million Series A financing round. Participants were new investor Lundbeckfonden as well as existing investor Novo A/S.
On 14-15 March 2016, London sets the scene for Cambridge Healthtech Institute's Inaugural conference, Cancer Biotherapeutics, presenting new developments, in-depth discussions and focused short courses from academia and industry with a strong focus on immunotherapy.
IO Biotech has received an InnoBooster grant from Innovation Fund Denmark to support the development of its in vivo checkpoint vaccine models